Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Closes on Public Offering, Raises $27.5M

NEW YORK (GenomeWeb News) – Rosetta Genomics said today it has closed its public offering, raising $27.5 million in gross proceeds.

The firm offered 5.5 million shares at $5 per share. Aegis Capital was the sole book-running manager for the offering. Rosetta granted the underwriter a 45-day option to purchase up to 825,000 additional shares to cover any overallotments.

The Israel-based developer of microRNA-based molecular diagnostics plans to use funds from the offering for general corporate purposes including repayment or refinancing of debt, capital investments, and R&D and product development efforts.

Rosetta filed a prospectus for the offering in June, at which time the company said it aimed to raise up to $35 million. Two weeks ago, it said it anticipated raising $27.7 million from an offering of 3 million shares, assuming a public offering price of $10.15 per share.

In afternoon trading on the Nasdaq, shares of Rosetta were up almost 4 percent at $4.40.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.